Prospecção in silico, in vitro e in vivo de derivados aminoquinolínicos e β-carbolínicos com potencial antimalárico
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
With 241 million new cases and 650,000 deaths estimated in 2020, malaria remains
one of the greatest public health challenges worldwide, with the highest incidence of
cases (94%) in sub-Saharan Africa. Among the Plasmodium species responsible for
human malaria, P. falciparum is the most prevalent in Africa and responsible for the
most serious infection, cerebral malaria. In the absence of an effective vaccine and
due to the spread of Plasmodium resistance to antimalarials available, there is an
urgent need to develop new drugs that are effective against P. falciparum. In this
context, alkaloids represent an important warning group that have been used as a tool
in the search for new drugs. Among the different classes of alkaloids existing in nature,
the quinoline and β-carboline stand out, which have different biological activities,
including antimalarials. Based on this assumption, this work controlled synthetics of 4
aminoquinolines and β-carbolines for their antimalarial potential in silico and in vitro in
order to select the most promising drugs for in vivo studies against experimental
cerebral malaria (ECM). The β-carbolines were initially tested against 35 molecular
targets of P. falciparum, selecting 7 with interaction with essential enzymes for the
metabolism of the parasite, which could cause its death. The physicochemical and
pharmacokinetic properties of absorption of these symptoms, as well as the quinoline
derivatives, were symptoms using computational tools. Cytotoxicity parameters were
evaluated in human lung fibroblasts (WI26VA4) and in human hepatocarcinoma cells
(HepG2) and an antiplasmodial activity was evaluated against chloroquine-resistant P.
falciparum strain (W2). A mechanism of action was investigated, in vitro, through
interaction with ferriprotoporphyrin or following nitric oxide synthesis. Finally, in vivo
antimalarial activity was determined by Peters' curative and/or suppressive testes,
performed in C57BL/6 mice infected with P. berghei ANKA and treated with the drug
candidates. In general, the molecules showed good oral bioavailability, predicted in
silico, with low cytotoxicity and adequate selectivity for the parasites in the in vitro
assays, highlighting quinolinic 3 and β-carbolinic 10. Quinolinic derivative 3 resulted in
important parasite multiplication inhibition (IMP) values on the 7th day post infection
(dpi) (76.9% (15mg/kg), 90.1% (30mg/kg) and 92.9% (50mg/kg)), with high survival
rates to the critical period of ECM and a better liver and kidney toxicity profile than
chloroquine. This result may be related to the interaction of the test compound with
ferriprotoporphyrin, identified through an in vitro assay, preventing the formation of
hemozoin crystals in the parasite's digestive vacuole, causing its death. Regarding the
in vivo activity of β-carboline alkaloids, compound 10 showed important IMP values at
the 5th dpi (67.92% (10mg/kg) and 82.07% (10mg/kg)) in the curative treatment
scheme and suppressive, respectively, with high rates of survival to the critical period
of ECM and absence of hemorrhage and vascular occlusion observed macro and
microscopically in brain tissue. However, despite survival, the animals developed
hyperparasitemia in the subsequent days, suggesting that the compound may have
weak antimalarial activity in vivo, but adequate anti-inflammatory activity to prevent
ECM. Such activity, determined in vitro through the reduction of nitric oxide synthesis
by peritoneal macrophages stimulated and treated with the test compound, may be
related to the interaction of compound 10 with the inducible nitric oxide synthase
enzyme (iNOS) predicted through molecular modeling. Together, our results suggest
that the two classes of compounds tested have important characteristics for
antimalarial drugs, highlighting the quinolinic derivative 3 and the β-carbolinic 10 as
HIT (bioactive) compounds, given their low IC50 values, high CC50 and IS, adequate
pharmacokinetic absorption profile and in silico prediction of good oral bioavailability.
We also suggest that the quinolinic derivative 3 is a candidate for an early lead
compound, as it presents IC50 in nM scale, reduction of parasitemia with values above
90%, high survival rate, protection against the development of ECM, in addition to Liver
and kidney safety. Therefore, the process of synthesizing the series of 4-
aminoquinoline and β-carboline derivatives in this study was promising, producing
antimalarial HITs.
Description
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

